A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
NCT ID: NCT00071799
Last Updated: 2019-10-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
358 participants
INTERVENTIONAL
2003-11-01
2007-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
See study AZA PH GL 2003 CL 001 E for information about the extension to this study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma
NCT00761722
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
NCT00102687
A Phase II Study of Maintenance With Azacitidine in MDS Patients
NCT00446303
5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
NCT01652781
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
NCT02775903
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Best supportive care (BSC) alone,
* Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or
* Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).
All three options included best supportive care. Neither the experimental group (azacitidine) nor any of the comparison/control options allowed use of erythropoietin.
Duration of Intervention: Patients will be treated until death, withdrawal, unacceptable toxicity or conclusion of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Azacitidine
Study Drug plus best supportive care. Treatment with erythropoietin was not permitted
Azacitidine
Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
Conventional Care
Physician choice of low dose cytarabine (plus best supportive care), standard chemotherapy (plus best supportive care) or best supportive care (only). Treatment with erythropoietin was not permitted
Physician Choice
Physician Choice was one of three options:
* Best supportive care (BSC) alone,
* Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or
* Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).
All three options included best supportive care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Azacitidine
Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
Physician Choice
Physician Choice was one of three options:
* Best supportive care (BSC) alone,
* Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or
* Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).
All three options included best supportive care
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be 18 years of age or older
* Have a life expectancy of at least 3 months
* Be unlikely to proceed to bone marrow or stem cell transplantation therapy following remission
* Have serum bilirubin levels less than or equal to 1.5 times the upper limit of normal range for the laboratory
* Have serum glutamic-oxaloacetic transaminase (aspartate aminotransferase) or serum glutamic-pyruvic transaminase (alanine aminotransferase) levels less than or equal to 2 times the upper limit of normal (unless these are considered to be related to transfusion-induced secondary hemosiderosis)
* Have serum creatinine levels less than or equal to 1.5 times the upper limit of normal
Exclusion Criteria
* Prior treatment with azacitidine;
* Prior history of acute myeloid leukemia (AML);
* Malignant disease diagnosed within prior 12 months;
* Metastatic disease;
* Hepatic tumors;
* Radiation, chemotherapy, cytotoxic therapy for non-MDS conditions within prior 12 months;
* Prior transplantation or cytotoxic therapy to treat MDS;
* Serious medical illness likely to limit survival to 12 months or less;
* Treatment with erythropoietin or myeloid growth factors during prior 21 days or androgenic hormones during prior 13 days;
* Active HIV, viral hepatitis type B or C;
* Treatment with investigational drugs during prior 30 days;
* Within the 28-day screening period, documented red cell folate deficiency, as evidenced by red blood cell folate (not serum folate) or vitamin B12 deficiency
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
CL Beach
Role: STUDY_DIRECTOR
Celgene Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama School of Medicine
Birmingham, Alabama, United States
Indiana University Cancer Center
Indianapolis, Indiana, United States
Washington University School of Medicine
St Louis, Missouri, United States
Mount Sinai Medical Center
New York, New York, United States
Case Western Reserve University
Cleveland, Ohio, United States
Oregon Cancer Center
Portland, Oregon, United States
Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania, United States
Froedtert Memorial Lutheran Hospital
Milwaukee, Wisconsin, United States
Liverpool Hospital
Liverpool, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
The Newcastle Mater Miseriecordiae Hospital
Warratah, New South Wales, Australia
Royal Brisbane Hospital
Hersten, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Peter MacCallum Cancer Institute
East Melbourne, Victoria, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
The Royal Perth Hospital
Perth, Western Australia, Australia
First Clinical Base - Clinic of Hematology, MHAT - Pleven
Pleven, , Bulgaria
MHAT "St George" Clinic of Hematology, Plovdiv
Plovdiv, , Bulgaria
III-rd Internal Department, District Dispensary for Oncology diseases with stationary(DDOncDIU)
Plovdiv, , Bulgaria
National Centre of Hematology and Transfusiology, Sofia
Sofia, , Bulgaria
Multiprofile Hospital for Active Treatment (MHAT), "St. Marina" Clinic of Hematology
Varna, , Bulgaria
University Multiprofile Hospital for Active Treatment "Sveta Marina"
Varna, , Bulgaria
Fakultni nemocnice Brno
Jihlavska, Brno, Czechia
Fakultni nemocnice Hradec Kralove
Sokolska, Hradec Kralove, Czechia
Fakultni Nemocnice Olomouc
Olomouc, , Czechia
Vseobecna Fakultni Nemocnice
Prague, , Czechia
Uslav Hematologie a Krevni Transfuze
Prague, , Czechia
Chu D'Angers
Angers, , France
Hopital Beaujon
Clichy, , France
Che De Lille
Lille, , France
Hospital Edouard Herriot
Lyon, , France
Institute Paoli Calmettes
Marseille, , France
Chu De Nantes
Nantes, , France
Hospital Saint Louis
Paris, , France
Hopital Cochin
Paris, , France
Centre Henri Becquerel
Rouen, , France
Chu Purpan
Toulouse, , France
Universitatsklinikum Benjamin Franklin
Hindenburgdamm, State of Berlin, Germany
Universitatsklinikum Bonn
Bonn, , Germany
Klinikum Chemnitz gGmbH
Chemnitz, , Germany
Universitatsklinikum Carl Gustav Carus
Dresden, , Germany
St Johannes Hospital
Duisburg, , Germany
Heinrich-Heine University Dusseldorf
Düsseldorf, , Germany
University Essen
Essen, , Germany
Gerorg-August-Universitat Gottingen
Göttingen, , Germany
Allgemeines Krankenhaus St. Georg
Hamburg, , Germany
Universitatsklinikum Hambur-Eppendorf
Hamburg, , Germany
Universitatsklinikum Kiel II
Kiel, , Germany
Universitatsklinikum Ulm
Ulm, , Germany
University Hospital-Attikon
Haidari, Athens, Greece
University General Hospital of Heraklio Voutes
Heraklio, Crete, Greece
District General Hospital of Athens
Athens, , Greece
General Hospital of Chest Disease
Athens, , Greece
University General Hospital of Ioannina
Ioannina, , Greece
University General Hospital of Patra Rio
Pátrai, , Greece
Orszagos Gyogyintezeti Kozpont
Budapest, , Hungary
University of Pecs, 1st Dept of Internal Medicine
Pécs, , Hungary
University of Szeged, 2nd Department of Internal Medicine
Szeged, , Hungary
Policlinico S. Orsola-Malpighi
Bologna, , Italy
Universita di Firenze
Florence, , Italy
Ospedale San Martino
Genova, , Italy
Instituto Nazionale Dei Tumori
Milan, , Italy
Centro Oncologico Modenese
Modena, , Italy
Ospedale San Eugenio
Roma, , Italy
Policlinico Gemelli
Roma, , Italy
Instituto Nazionale Tumori "Regina Elena"
Roma, , Italy
Ospedale Casa Sollievo Della Sofferenza - Irrc
San Giovanni Rotondo, , Italy
Universita Degli Studi Di Sassari
Sassari, , Italy
VU University Medical Center Amsterdam
Amsterdam, , Netherlands
Univ Hospital St. Radboud
Nijmejen, , Netherlands
Samodzielny Publiczny Szpital Kliniczny Nr 1
Gdansk, , Poland
Wojewodzki Szpital Specjalistyczny
Lodz, , Poland
Samodzielny Publiczny Szpital Kliniczny
Lublin, , Poland
Wojskowy Instytut Medyczny
Warsaw, , Poland
Samodzelny Publiczny Centralny Szpital Kliniczny
Warsaw, , Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1
Wroclaw, , Poland
Burdenko Central Military Clinical Hospital
Moscow, , Russia
Blokhin Cancer Research Center
Moscow, , Russia
Scientific Haematology Center, Moscow
Moscow, , Russia
Institute of Haematology & Blood Transfusion
Saint Petersburg, , Russia
Pavlov State Medical University
Saint Petersburg, , Russia
Pavlov State Medical University
Saint Petersburg, , Russia
City Hospital #31
Saint Petersburg, , Russia
Hospital Santa Creu I Sant Pau
Barcelona, , Spain
Hospital Clinic
Barcelona, , Spain
Hospital Universitario Germans Trias I Pujol
Barcelona, , Spain
Hospital de Leon
León, , Spain
Hospital Universitario De La Princesa
Madrid, , Spain
Hospital Ramon Y Cajal
Madrid, , Spain
Hospital La Paz, Madrid
Madrid, , Spain
Hospital Clinico San Carlos
Madrid, , Spain
Hospital Son Llatzer
Palma de Mallorca, , Spain
Hospital Universitario Del Salamanca
Salamanca, , Spain
Hospital Universitario La Fe
Valencia, , Spain
Sahlgrenska University Hospital
Gothenburg, , Sweden
Lund Universtiy Hospital
Lund, , Sweden
University Hospital MAS
Malmo, , Sweden
Huddinge University Hospital
Stockholm, , Sweden
Uppsala University Hospital
Uppsala, , Sweden
Royal Bournemouth General Hospital
Bournemouth, , United Kingdom
St. Bartholomew's Hospital
London, , United Kingdom
Kings College Hospital NHS Trust
London, , United Kingdom
Christie Hospital
Manchester, , United Kingdom
Norfolk and Norwich University Hospital
Norwich, , United Kingdom
John Radcliffe Hospital
Oxford, , United Kingdom
Royal Cornwall Hospital
Truro, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb 1;28(4):562-9. doi: 10.1200/JCO.2009.23.8329. Epub 2009 Dec 21.
Fenaux P, Gattermann N, Seymour JF, Hellstrom-Lindberg E, Mufti GJ, Duehrsen U, Gore SD, Ramos F, Beyne-Rauzy O, List A, McKenzie D, Backstrom J, Beach CL. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol. 2010 Apr;149(2):244-9. doi: 10.1111/j.1365-2141.2010.08082.x. Epub 2010 Feb 5.
Santini V, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Silverman LR, List A, Gore SD, Seymour JF, Backstrom J, Beach CL. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol. 2010 Aug;85(2):130-8. doi: 10.1111/j.1600-0609.2010.01456.x. Epub 2010 Apr 12.
Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellstrom-Lindberg E, Santini V, List AF, Gore SD, Backstrom J, McKenzie D, Beach CL. Effects of azacitidine compared with conventional care regimens in elderly (>/= 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2010 Dec;76(3):218-27. doi: 10.1016/j.critrevonc.2010.04.005. Epub 2010 May 6.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.
Gore SD, Fenaux P, Santini V, Bennett JM, Silverman LR, Seymour JF, Hellstrom-Lindberg E, Swern AS, Beach CL, List AF. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013 Jul;98(7):1067-72. doi: 10.3324/haematol.2012.074831. Epub 2013 Apr 12.
Related Links
Access external resources that provide additional context or updates about the study.
Study record for the extension study of AZA PH GL 2003 CL 001
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AZA PH GL 2003 CL001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.